Aclidinium bromide: An alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease;Bromuro deAclidinio:Una Alternativa de Anticolinérgico Inhalado de Larga Duración para el Manejo de Enfermedad Pulmonar Obstructiva Crónica

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 1017-1028

  Andrew Woods, J ^a,b   Nealy, Kimberly L ^a   Barrons, Robert W ^a  

^a WINGATE UNIVERSITY   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FALLING; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; TOOTH PAIN; TREATMENT DURATION; VOMITING;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; TROPANES;

EID: 84880069643     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1S002     Document Type: Article

References (48)

1. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: World Health Organization/National Heart, Lung, and Blood Institute, 2011. http://www.goldcopd.com/ (accessed 2012 Nov 1).
2. National Heart, Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health. 2011. http://www.nhlbi.nih.gov/resources/ docs/cht-book.htm (accessed 2012 Nov 1)
3. Mannino DM, Homa DM, Akinbami LJ, Redd SC, Ford ES. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Respir Care 2002;47:1148-9.
4. Centers for Disease Control and Prevention. Division of vital statistics. Death: preliminary data for 2008. www.cdc.gov/nchs/data/nvsr/nvsr60/ nvsr60_04.pdf (accessed November 2012)
5. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989;96:984-7.
6. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.
7. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
8. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404.
9. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511-20.
10. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:297-304.
11. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331: 740-51.
12. Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther 2012;25:193-9.
13. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in health participants. J Clin Pharmacol 2009; 49:1239-46.
14. Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010; 39:283-90.
15. Schelfhout VJ, Ferrer P, Jansat JM, et al. Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol 2010;69:458-64.
16. Schmid K, Pascual S, Garcia Gil E, Ortiz S, Jasat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal of impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther 2010;32:1798-812.
17. Product information. Tudorza Pressair (aclidinium bromide) inhalation powder. St Louis, MO: Forest Pharmaceuticals, October 2012.
18. Product information. Spiriva HandiHaler (tiotropium bromide) inhalation powder. Ingelheim, Germany: Boehringer Ingelheim International GmbH, October 2013.
19. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012;141:745-52.
20. Prat M, Fernandez D, Buil MA, et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxyl(di-2-thienyl) acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicy clo[2.2.2]octane bromide (aclidinium bromide). J Med Chem 2009;52:5076-92.
21. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009;330:660-8.
22. Joos GF, Schelfhout VJ, Pauwels RA, et al. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:865-72.
23. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010;7:331-6.
24. Chanez P, Burge PS, Dahl R, et al. Aclidinium bromide provides longacting bronchodilation in patients with COPD. Pulm Pharmacol Ther 2010;23:15-21.
25. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12:55.
26. Singh D, Magnussen H, Kirsten A, et al. A randomized, placebo-and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012;25:248-53.
27. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9:90-101.
28. Data on file. Clinical study report no. LAS-MD-36. Forest Research Institute, Inc., Jersey City, NJ, April 22, 2011.
29. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830-6.
30. Data on file. Clinical study report no. LAS-MD-35. Forest Research Institute, Inc., Jersey City, NJ, December 27, 2011.
31. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
32. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111-24.
33. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
34. Partridge ME, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-8.
35. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72.
36. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2:75-9.
37. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:111-24.
38. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703.
39. Lasseter KC, Aubets J, Chuecos F, Garcia GE. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in health subjects. J Clin Pharmacol 2011;51:923-32.
40. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA 2008;300:1439-50.
41. Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010;5:197-208.
42. Bateman ED, Tashkim D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010;104: 1460-72.
43. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-the FDA's conclusions. N Engl J Med 2010;363:1097-9.
44. de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012;50:403-12.
45. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009;47:460-8.
46. Red Book Online. Micromedex 2.0. 2012. www.thomsonhc.com (accessed 2012 Nov 29).
47. Drugstore. com. http://www.drugstore.com (accessed 2012 Nov 29).
48. Magnussen H, Watz H, Zimmermann I, et al. Peak inspiratory flow through the Genuair inhaler in patients with moderate to severe COPD. Respir Med 2009;103:1832-7.